Search Results

Policy

CorMedix Inc. Receives FDA Feedback on Potential Label Expansion

CorMedix Inc. announced that the U.S. Food and Drug Administration has provided feedback to the Company’s request to discuss development plans for additional indications for DefenCath.

June 18, 2024

·

4 min read

Pharm Country

CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath

CorMedix Inc. announced that the Center for Medicare & Medicaid Services has determined that DefenCath® qualifies for pass-through status under the hospital Out-Patient Prospective Payment System.

June 6, 2024

·

3 min read

Business

CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

CorMedix Inc. today announced that it has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath ® (taurolidine and heparin).

May 28, 2024

·

3 min read

Pharm Country

CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

CorMedix Inc. today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath ® meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024.

April 19, 2024

·

4 min read

Business

CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, announced financial results for the first quarter ended March 31, 2024 and provided an update on its business.

May 9, 2024

·

7 min read

Pharm Country

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

CorMedix Inc. announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath®.

April 8, 2024

·

3 min read

Pharm Country

CorMedix Inc. to Participate in Two Upcoming Investor Conferences - May 10, 2024

CorMedix Inc. today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York.

May 10, 2024

·

1 min read

Pharm Country

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

CorMedix Inc. today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use.

April 15, 2024

·

4 min read

Pharm Country

CorMedix Inc. to Present at the Needham Annual Healthcare Conference

CorMedix Inc. (Nasdaq: CRMD) today announced that management will be participating in a fireside chat and investor meetings at the Needham 23rd Annual Healthcare Conference, being held virtually on April 8 – 11, 2024.

March 27, 2024

·

1 min read

Pharm Country

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

CorMedix Inc. today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024.

April 11, 2024

·

3 min read